Clinical trials: Neuroendocrine Tumor Metastatic
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
This phase I trial studies the side effects and best dose of STAT3 inhibitor WP1066 in treating patients with malignant glioma that has come back or melanoma that has spread to the brain and is growing, spreading, or getting…
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Recurrent Brain Neoplasm, Recurrent Glioblastoma
- Trial name
- NCT01904123
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, STAT3 Inhibitor WP1066
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Melanoma, Skin Cancer
Cryoablation+Ipilimumab+Nivolumab in Melanoma
The aim of this study is to find out whether the combination of two approved drugs, ipilimumab and nivolumab, in combination with cryoablation are safe and effective for participants who have an unresectable melanoma that is…
- Trial name
- NCT05779423
- Testing
- Ipilimumab, Nivolumab, Cryoablation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts General Hospital
Non-Small Cell Lung Cancer, Metastatic Melanoma
A Study to Investigate 14C-bemcentinib in Healthy Male Subjects
The aims of this Study were to determine: How much of the Study Drug (bemcentinib) ends up in urine and faeces How much of the Study Drug and its breakdown products get into the bloodstream The breakdown products (metabolites) of…
- Conditions
- Non-Small Cell Lung Cancer, Metastatic Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- 8479217 (NCT06469138)
- Testing
- Bemcentinib
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- BerGenBio ASA
Melanoma Metastatic, Melanoma of Skin
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
Why the research is needed: Researchers are looking for a better way to treat melanoma that has spread or cannot be removed surgically.
- Conditions
- Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent
- Trial name
- NCT06784648
- Testing
- pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution)
- Where
- 4 sites in Germany, Spain and 1 more
- Volunteers
- 35 people
- Sponsor
- BioInvent International AB
Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Background: Cancers of the nasal cavity or skull base are rare. They often are not diagnosed until they are at an advanced stage, and they often spread to other parts of the body.
- Conditions
- Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma, Metastatic Sinonasal Adenocarcinoma, Locally Advanced Sinonasal Adenocarcinoma
- Trial name
- NCT06176989
- Testing
- Enasidenib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma, Nausea
Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin
The purpose of this study is to observe the incidence of nausea with systemic chemotherapy that includes consecutive days (more than one day)of cisplatin medication.
- Trial name
- NCT00716560
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hereditary Thyroid Gland Medullary Carcinoma, Locally Advanced Thyroid Gland Medullary Carcinoma
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
This phase II trial studies how well sorafenib tosylate works in treating patients with medullary thyroid cancer that has spread to other parts of the body (metastatic), spread to the tissue surrounding the thyroid (locally…
- Conditions
- Hereditary Thyroid Gland Medullary Carcinoma, Locally Advanced Thyroid Gland Medullary Carcinoma, Multiple Endocrine Neoplasia Type 2A, Multiple Endocrine Neoplasia Type 2B
- Trial name
- NCT00390325
- Testing
- Sorafenib Tosylate
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Skin Cancer
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00002882
- Testing
- Aldesleukin (IL-2), Recombinant Interferon Alfa (IFN-A), Cisplatin
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines made from peptide 946 may make the body build an immune response to kill tumor cells. Combining these vaccines with proteins from the tetanus vaccine, and/or with either QS21 or Montanide ISA-51 may be an…
- Trial name
- NCT00003224
- Testing
- QS21, IFA (incomplete Freund's adjuvant), p946
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Virginia
Metastatic Melanoma
Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes
Recent progresses have been made in the treatment of metastatic melanoma, nevertheless improved patient survival is still limited because of primary resistance and relapses.
- Trial name
- EXOSOMES (NCT02310451)
- Testing
- blood test
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Malignant Melanoma
An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma
This observational study will evaluate the effectiveness of BRAF inhibitors and current therapies in patients with newly diagnosed metastatic melanoma with or without BRAF V600 mutation.
- Trial name
- NCT02143999
- Where
- 24 sites in Italy
- Volunteers
- 403 people
- Sponsor
- Hoffmann-La Roche
Merkel Cell Carcinoma
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma
This study will test the use of comprehensive ablative radiation therapy (CART), with the immunotherapy drug avelumab, in people with Merkel cell carcinoma (MCC) that has progressed after treatment and cannot be removed with…
- Trial name
- NCT04792073
- Testing
- Avelumab, Comprehensive Ablative Radiation Therapy
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Skin Cancer, Metastatic Melanoma
Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes
Background: One experimental treatment for certain types of cancer is cell therapy, which involves collecting lymphocytes (white blood cells) from a tumor, growing them in the laboratory in large numbers, and then modifying the…
- Trial name
- NCT01236573
- Testing
- Fludarabine, Cyclophosphamide, IL-12 transduced TIL
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Intraocular Melanoma, Melanoma (Skin)
PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Biological therapies, such as thalidomide, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00238329
- Testing
- PEG-interferon alfa-2b, thalidomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Melanoma
Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)
This is an expanded access program (EAP) for participants who have progressed after prior systemic therapy including ipilimumab, and V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor or mitogen-activated protein…
- Trial name
- NCT02083484
- Testing
- Pembrolizumab
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Background: Cell therapy is an experimental cancer therapy. It takes young tumor infiltrating lymphocytes (Young TIL) cells from a person s tumors and grows them in a lab. Then they are returned to the person.
- Trial name
- NCT02621021
- Testing
- young TIL, Pembrolizumab, Aldesleukin
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Melanomas Excised in Primary Care vs Secondary Care Excision
Melanoma is the most dangerous skin cancer and is becoming commoner, largely due to increased foreign holidays and use of sun-beds. Melanoma usually begins as a new or changing mole.
- Trial name
- MelEx (NCT03169036)
- Volunteers
- 9,367 people
- Sponsor
- University of Aberdeen
Melanoma (Skin)
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines made from a person's white blood cells may make the body build an immune response and kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have…
- Trial name
- NCT00019487
- Testing
- aldesleukin, gp209-2M antigen, incomplete Freund's adjuvant
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
RATIONALE: Interleukin-21 may stimulate white blood cells, including natural killer cells, to kill melanoma cells. PURPOSE: This phase II trial is studying the side effects and how well interleukin-21 works in treating patients…
- Trial name
- NCT00514085
- Testing
- recombinant human interleukin-21, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 7 sites in Canada
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group
Unresectable or Metastatic Melanoma
PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma
This prospective, single-center pilot study is being performed to find out whether Zr-89 crefmirlimab berdoxam "CD8 PET/CT" scans can improve the effectiveness of the tumor-infiltrating lymphocyte (TIL) therapy called lifileucel…
- Trial name
- PICSTAT (NCT07700121)
- Testing
- Resection of PET (high) and PET (low) Tumors, Lifileucel Manufacturing Clinical v Research, Chemotherapy Regimen
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.